Mediating Passive Tumor Accumulation through Particle Size, Tumor Type, and Location
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
As the enhanced permeation and retention (EPR) effect continues to be a controversial topic in nanomedicine, we sought to examine EPR as a function of nanoparticle size, tumor model, and tumor location, while also evaluating tumors for EPR mediating factors such as microvessel density, vascular permeability, lymphatics, stromal content, and tumor-associated immune cells. Tumor accumulation was evaluated for 55 × 60, 80 × 180, and 80 × 320 nm PRINT particles in four subcutaneous flank tumor models (SKOV3 human ovarian, 344SQ murine nonsmall cell lung, A549 human nonsmall cell lung, and A431 human epidermoid cancer). Each tumor model revealed specific particle accumulation trends with evident particle size dependence. Immuno-histochemistry staining revealed differences in tumor microvessel densities that correlated with overall tumor accumulation. Immunofluorescence images displayed size-mediated tumor penetration with signal from the larger particles concentrated close to the blood vessels, while signal from the smaller particle was observed throughout the tissue. Differences were also observed for the 55 × 60 nm particle tumor penetration across flank tumor models as a function of stromal content. The 55 × 60 nm particles were further evaluated in three orthotopic, metastatic tumor models (344SQ, A549, and SKOV3), revealing preferential accumulation in primary tumors and metastases over healthy tissue. Moreover, we observed higher tumor accumulation in the orthotopic lung cancer models than in the flank lung cancer models, whereas tumor accumulation was constant for both orthotopic and flank ovarian cancer models, further demonstrating the variability in the EPR effect as a function of tumor model and location.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
The effect of particle design on cellular internalization pathways
Gratton, S. E. A., Ropp, P. A., Pohlhaus, P. D., Luft, J. C., Madden, V. J., Napier, M. E., & DeSimone, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801763105 · Cited by 2,918
Self-citationDrug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Regulation of transport pathways in tumor vessels: Role of tumor type and microenvironment
Hobbs, S. K., Monsky, W. L., Yuan, F., Roberts, W. G., Griffith, L., Torchilin, V. P., & Jain, R. K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4607 · Cited by 2,438
Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size
Cabral, H., Matsumoto, Y., Mizuno, K., Chen, Q., Murakami, M., Kimura, M., Terada, Y., Kano, M. R., Miyazono, K., Uesaka, M., et al. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.166 · Cited by 2,429
Openings Between Defective Endothelial Cells Explain Tumor Vessel Leakiness
Hashizume, H., Baluk, P., Morikawa, S., McLean, J. W., Thurston, G., Roberge, S., Jain, R. K., & McDonald, D. M. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)65006-7 · Cited by 1,689
Tumor-Associated Macrophages as Major Players in the Tumor Microenvironment
Chanmee, T., Ontong, P., Konno, K., & Itano, N. (2014) · Cancers · doi:10.3390/cancers6031670 · Cited by 1,538
Mediating Tumor Targeting Efficiency of Nanoparticles Through Design
Perrault, S. D., Walkey, C., Jennings, T., Fischer, H. C., & Chan, W. C. W. (2009) · Nano Letters · doi:10.1021/nl900031y · Cited by 1,513
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Self-citation
Cited by
Nanotechnology for Multimodal Synergistic Cancer Therapy
Fan, W., Yung, B., Huang, P., & Chen, X. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00258 · Cited by 1,791
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
Zhao, Z., Ukidve, A., Krishnan, V., & Mitragotri, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.002 · Cited by 444
Progress, challenges, and future of nanomedicine
Zhang, C., Yan, L., Wang, X., Zhu, S., Chen, C., Gu, Z., & Zhao, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101008 · Cited by 318
Hu, C., Cun, X., Ruan, S., Liu, R., Xiao, W., Yang, X., Yang, Y., Yang, C., & Gao, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.03.046 · Cited by 276
Cancer nanotechnology: current status and perspectives
Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 266
Xiao, W., Ruan, S., Yu, W., Wang, R., Hu, C., Liu, R., & Gao, H. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00475 · Cited by 84
Ultrabright Fluorescent Organic Nanoparticles Based on Small‐Molecule Ionic Isolation Lattices**
Chen, J., Fateminia, S. M. A., Kacenauskaite, L., Bærentsen, N., Grønfeldt Stenspil, S., Bredehoeft, J., Martinez, K. L., Flood, A. H., & Laursen, B. W. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202100950 · Cited by 55
Cong, Z., Yang, F., Cao, L., Wen, H., Fu, T., Ma, S., Liu, C., Quan, L., & Liao, Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s185726 · Cited by 23
“suggesting that a size threshold for tumor penetration with a nanoparticle of 10–40 nm but not $50 nm would facilitate the accumulation in the interior of tumor tissues.(22,35,36,38,39) However, CLSM was unable to reveal the spatial distribution characteristics within the whole tumors.”
BackgroundHow does the gut microbiome influence immune checkpoint blockade therapy?
Almonte, A. A., Rangarajan, H., Yip, D., & Fahrer, A. M. (2021) · Immunology & Cell Biology · doi:10.1111/imcb.12423 · Cited by 21
“A previous study has shown that intravenously injected particulates approximately the size of bacteria preferentially accumulate within tumor masses.(51) In addition, past reports have already suggested that tumors, which have a hypoxic environment ideal for anaerobic bacterial growth, are viable locations for bacteri…”
Background
Metadata
- Authors
- Perry, J. L., Reuter, K. G., Luft, J. C., Pecot, C. V., Zamboni, W., & DeSimone, J. M.
- Venue
- Nano Letters
- Publisher
- American Chemical Society (ACS)
- Published
- 2017-04-11
- Volume
- 17
- Issue
- 5
- Pages
- 2879-2886
- ISSN
- 1530-6984 (ISSN-L)
- 1530-6992
- OpenAlex
- W2595421589
- Cited by
- 255
- References
- 37
- FWCI
- 10.41
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.